Oryzon Genomics SA (id:4763 ORY)
1.57 EUR
Opening hours: 09:00 - 17:30 (Central European Standard Time: 11/22/2024 1:38:36 AM)
Exchange closed, opens in 7 hours 21 minutes
-0.63 EUR (-0.63%)
-4.27 EUR (-4.27%)
-10.90 EUR (-10.90%)
-18.23 EUR (-18.23%)
-22.28 EUR (-22.28%)
-42.17 EUR (-42.17%)
-65.03 EUR (-65.03%)
About Oryzon Genomics SA
Market Capitalization 103.02M
Oryzon Genomics S.A., a clinical stage biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS disorders. Its clinical phase compounds include iadademstat (ORY-1001), a selective LSD1 inhibitor that is in Phase II trials for oncology; and vafidemstat (ORY-2001), a CNS-optimized LSD1 inhibitor, which is in Phase II trials for the treatment of CNS and psychiatric diseases. Its product candidates also comprise ORY-3001, an LSD1 inhibitor that is in preclinical development for the treatment of non-oncological diseases. The company was founded in 2000 and is based in Cornellà de Llobregat, Spain.
| Headquarters (address) |
Sant Ferran 74 Cornellà de Llobregat 08940 Spain |
| Phone | 34 93 515 13 13 |
| Website | https://www.oryzon.com |
| Employees | 46 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Ticker | ORY |
| Exchange | Madrid Stock Exchange |
| Currency | EUR |
| 52 week range | 1.55 - 2.38 |
| Market Capitalization | 103.02M |
| P/E trailing | -28.69 |
| P/E forward | -9.53 |
| Price/Sale | 6.51 |
| Price/Book | 1.21 |
| Beta | 0.646 |
| EPS | -0.060 |
| EPS Spain (ID:221, base:139) | 0.792 |